MedPath

Cabozantinib/Nivolumab Combination Findings Further Inform RCC Care - OncLive

CheckMate 9ER trial data shows cabozantinib plus nivolumab improves PFS, OS, and ORR in RCC, similar to other TKI/immunotherapy combinations, though favorable-risk patients see less benefit. Combination regimens are more tolerable than sunitinib, with potential post-discontinuation benefits.


© Copyright 2025. All Rights Reserved by MedPath